IP Library Patent Application 10490581
Patent Application
App. No. 10/490,581

Methods of controlling proliferation of cancer cells and cell death

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/490,581
Abstract

This invention demonstrates that the PEG10 protein suppresses apoptosis and promotes cancer cell growth. Furthermore, PEG10 protein was found to be degraded through interaction with SIAH1 protein. This invention provides methods of regulating cell growth and cell death using the PEG10 protein. Furthermore, the present invention provides methods of screening for novel anticancer agents which use the PEG10 protein. The screening of this invention enables development of pharmaceutical agents that induce apoptosis and suppress cell growth by specifically targeting cancer cells. In particular, since the PEG10 protein is specifically expressed in hepatoma cells, it is an ideal target molecule for diagnosis and treatment of hepatoma.

Claims (23)

1 . A method of promoting or suppressing cell growth, wherein the method comprises the step of increasing or decreasing PEG10 protein level in a cell, respectively.

2 . A method of suppressing or promoting cell death, wherein the method comprises the step of increasing or decreasing PEG 10 protein level in a cell, respectively.

3 . The method of claim 1 or 2 , wherein the step of increasing or decreasing PEG10 protein level in a cell is the step of suppressing or promoting the interaction level of the PEG10 protein with a SIAH protein in a cell.

4 . The method of claim 1 or 2 , wherein the step of increasing PEG10 protein level in a cell is the step of exogenously expressing the PEG 10 gene.

5 . The method of claim 1 or 2 , wherein the step of decreasing PEG10 protein level in a cell is the step of transferring antisense polynucleotides against the PEG10 gene into a cell, or expressing the polynucleotides in a cell.

6 . The method of claim 1 or 2 , wherein the cell is a cancer cell.

7 . The method of claim 6 , wherein the cancer cell is a hepatoma cell.

8 . The method of claim 7 , wherein the hepatoma cell is a hepatocellular carcinoma cell.

9 . A method of screening for compounds comprising the activity of regulating cell growth or cell death, the method comprising the steps of:

(a) detecting PEG10 gene expression level in a cell in the presence of a sample comprising a test compound; and

(b) selecting compounds comprising the activity of increasing or decreasing the expression level.

10 . A method of screening for compounds comprising the activity of regulating cell growth or cell death, the method comprising the steps of:

(a) detecting the interaction between the PEG10 protein and a SIAH protein in the presence of a sample comprising a test compound; and

(b) selecting compounds comprising the activity of increasing or decreasing the interaction.

11 . A method of screening for compounds comprising the activity of regulating cell growth or cell death, the method comprising the steps of:

(a) culturing cells exogenously expressing the PEG10 protein in the presence of a sample comprising a test compound; and

(b) selecting compounds comprising the activity of increasing or decreasing growth or cell death of the cells.

12 . A pharmaceutical composition for preventing or treating cell proliferative diseases, comprising compounds able to be isolated by a method of any one of claims 9 to 11 .

13 . The pharmaceutical composition of claim 12 , comprising an antisense polynucleotide against the PEG10 gene.

14 . A method of testing or diagnosing hepatoma, wherein the method comprises the step of detecting structural changes or aberrant expression of the PEG] 0 gene and/or SIAH gene.

15 . The method of testing or diagnosis of claim 14 , wherein the hepatoma is a hepatocellular carcinoma.

16 . A reagent for testing or diagnosing hepatoma, comprising a polynucleotide which comprises a portion of the PEG10 gene or SIAH gene nucleotide sequence, or a portion of a complementary strand thereof, or an antibody that binds to the PEG10 protein or SIAH protein.

17 . The reagent for testing or diagnosing hepatoma of claim 16 , wherein the hepatoma is a hepatocellular carcinoma.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME FROM ONCOTHERAPHY SCIENCE, INC. TO ONCOTHERAPY SCIENCE, INC. PREVIOUSLY RECORDED ON REEL 018669 FRAME 0205. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Feb 5, 2007
From: THE UNIVERSITY OF TOKYO
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 018853/0223 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2006
From: THE UNIVERSITY OF TOKYO
To: ONCOTHERAPHY SCIENCE, INC.
Reel/Frame 018669/0205 →
TRANSLATION OF JAPANESE NATIONAL UNIVERSITY CORPORATION LAW PROVIDING, IN PART, THE SUCCESSION OF RIGHTS AND OBLIGATIONS CURRENTLY ATTRIBUTABLE TO THE NATIONAL GOVERNMENT TO THE UNIVERSITY OF TOKYO Recorded Nov 10, 2006
From: JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO
To: THE UNIVERSITY OF TOKYO
Reel/Frame 018507/0142 →
TRANSLATION OF JAPANESE CERTIFICATE OF TOTAL HISTORICAL RECORD INDICATING THAT THE UNIVERSITY OF TOKYO WAS ESTABLISHED AS A NATIONAL UNIVERSITY CORPORATION UNDER THE JAPANESE NATIONAL UNIVERSITY CORPORATION LAW Recorded Nov 10, 2006
From: JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO
To: THE UNIVERSITY OF TOKYO
Reel/Frame 018507/0184 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS TO INSERT TOKYO INTO THE ADDRESS PREVIOUSLY RECORDED ON REEL 015317 FRAME 0941. ASSIGNOR HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 15, 2005
From: NAKAMURA, YUSUKE; FURUKAWA, YOICHI
To: JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO; ONCOTHERAPY SCIENCE, INC.
Reel/Frame 016339/0614 →